Full Text Journal Articles by
Author Andrew S Kraft

Advertisement

Find full text journal articles






PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.

James T Lim, Neha Singh, Libia A Leuvano, Valerie S Calvert, Emanuel F Petricoin, David T Teachey, Richard B Lock, Megha Padi, Andrew S Kraft, Sathish K R Padi,

Despite significant progress in understanding the genetic landscape of T-cell acute lymphoblastic leukemia (T-ALL), the discovery of novel therapeutic targets has been difficult. Our results demonstrate that the levels of PIM1 protein kinase is elevated in early T-cell precursor ALL (ETP-ALL) but not in mature T-ALL primary samples. Small-molecule PIM ... Read more >>

Mol Cancer Ther (Molecular cancer therapeutics)
[2020, 19(9):1809-1821]

Cited: 0 times

View full text PDF listing >>



Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth.

Sathish K R Padi, Neha Singh, Jeremiah J Bearss, Virginie Olive, Jin H Song, Marina Cardó-Vila, Andrew S Kraft, Koichi Okumura,

The Pim and AKT serine/threonine protein kinases are implicated as drivers of cancer. Their regulation of tumor growth is closely tied to the ability of these enzymes to mainly stimulate protein synthesis by activating mTORC1 (mammalian target of rapamycin complex 1) signaling, although the exact mechanism is not completely understood. ... Read more >>

Proc Natl Acad Sci U S A (Proceedings of the National Academy of Sciences of the United States of America)
[2019, 116(41):20505-20510]

Cited: 1 time

View full text PDF listing >>



Advertisement

Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.

Shilpak Chatterjee, Paramita Chakraborty, Anusara Daenthanasanmak, Supinya Iamsawat, Gabriela Andrejeva, Libia A Luevano, Melissa Wolf, Uday Baliga, Carsten Krieg, Craig C Beeson, Meenal Mehrotra, Elizabeth G Hill, Jeffery C Rathmell, Xue-Zhong Yu, Andrew S Kraft, Shikhar Mehrotra,

PURPOSE:Adoptive T-cell therapy (ACT) of cancer, which involves the infusion of ex vivo-engineered tumor epitope reactive autologous T cells into the tumor-bearing host, is a potential treatment modality for cancer. However, the durable antitumor response following ACT is hampered either by loss of effector function or survival of the antitumor ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2019, 25(3):1036-1049]

Cited: 6 times

View full text PDF listing >>



Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase.

Jin H Song, Neha Singh, Libia A Luevano, Sathish K R Padi, Koichi Okumura, Virginie Olive, Stephen M Black, Noel A Warfel, David W Goodrich, Andrew S Kraft,

Cancer resistance to PI3K inhibitor therapy can be in part mediated by increases in the PIM1 kinase. However, the exact mechanism by which PIM kinase promotes tumor cell resistance is unknown. Our study unveils the pivotal control of redox signaling by PIM kinases as a driver of this resistance mechanism. ... Read more >>

Mol. Cancer Ther. (Molecular cancer therapeutics)
[2018, 17(12):2710-2721]

Cited: 6 times

View full text PDF listing >>



Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents.

Andrea L Casillas, Rachel K Toth, Alva G Sainz, Neha Singh, Ankit A Desai, Andrew S Kraft, Noel A Warfel,

Purpose: Patients develop resistance to antiangiogenic drugs, secondary to changes in the tumor microenvironment, including hypoxia. PIM kinases are prosurvival kinases and their expression increases in hypoxia. The goal of this study was to determine whether targeting hypoxia-induced PIM kinase expression is effective in combination with VEGF-targeting agents. The rationale ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2018, 24(1):169-180]

Cited: 8 times

View full text PDF listing >>



Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.

Simran Sindhu, Lana H Gimber, Lee Cranmer, Ali McBride, Andrew S Kraft,

Angiosarcomas are tumors of malignant endothelial origin that have a poor prognosis with a five-year survival of less than 40%. These tumors can be found in all age groups, but are more common in older patients; with the cutaneous form most common in older white men. Combined modality therapy including ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2017, 5(1):58]

Cited: 17 times

View full text PDF listing >>



Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.

Sathish K R Padi, Libia A Luevano, Ningfei An, Ritu Pandey, Neha Singh, Jin H Song, Jon C Aster, Xue-Zhong Yu, Shikhar Mehrotra, Andrew S Kraft,

New approaches are needed for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) who fail to achieve remission with chemotherapy. Analysis of the effects of pan-PIM protein kinase inhibitors on human T-ALL cell lines demonstrated that the sensitive cell lines expressed higher PIM1 protein kinase levels, whereas T-ALL ... Read more >>

Oncotarget (Oncotarget)
[2017, 8(18):30199-30216]

Cited: 9 times

View full text PDF listing >>



PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.

Noel A Warfel, Alva G Sainz, Jin H Song, Andrew S Kraft,

Intratumoral hypoxia is a significant obstacle to the successful treatment of solid tumors, and it is highly correlated with metastasis, therapeutic resistance, and disease recurrence in cancer patients. As a result, there is an urgent need to develop effective therapies that target hypoxic cells within the tumor microenvironment. The Proviral ... Read more >>

Mol Cancer Ther (Molecular cancer therapeutics)
[2016, 15(7):1637-1647]

Cited: 9 times

View full text PDF listing >>



Insulin receptor substrate 1 is a substrate of the Pim protein kinases.

Jin H Song, Sathish K R Padi, Libia A Luevano, Mark D Minden, Daniel J DeAngelo, Gary Hardiman, Lauren E Ball, Noel A Warfel, Andrew S Kraft,

The Pim family of serine/threonine protein kinases (Pim 1, 2, and 3) contribute to cellular transformation by regulating glucose metabolism, protein synthesis, and mitochondrial oxidative phosphorylation. Drugs targeting the Pim protein kinases are being tested in phase I/II clinical trials for the treatment of hematopoietic malignancies. The goal of these ... Read more >>

Oncotarget (Oncotarget)
[2016, 7(15):20152-20165]

Cited: 9 times

View full text PDF listing >>



Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors.

Ningfei An, Ying Xiong, Amanda C LaRue, Andrew S Kraft, Bo Cen,

Mesenchymal-epithelial transition (MET) blockade offers a new targeted therapy particularly in those cancers with MET amplification. However, the efficacy and the duration of the response to MET inhibitors are limited by the emergence of drug resistance. Here, we report that resistance to small-molecule inhibitors of MET can arise from increased ... Read more >>

Cancer Res. (Cancer research)
[2015, 75(24):5318-5328]

Cited: 10 times

View full text PDF listing >>



PIM kinase (and Akt) biology and signaling in tumors.

Noel A Warfel, Andrew S Kraft,

The initiation and progression of human cancer is frequently linked to the uncontrolled activation of survival kinases. Two such pro-survival kinases that are commonly amplified in cancer are PIM and Akt. These oncogenic proteins are serine/threonine kinases that regulate tumorigenesis by phosphorylating substrates that control the cell cycle, cellular metabolism, ... Read more >>

Pharmacol Ther (Pharmacology & therapeutics)
[2015, 151:41-49]

Cited: 53 times

View full text PDF listing >>



Regulation of prostate stromal fibroblasts by the PIM1 protein kinase.

Marina Y Zemskova, Jin H Song, Bo Cen, Javier Cerda-Infante, Viviana P Montecinos, Andrew S Kraft,

The PIM1 oncogene is over-expressed in human prostate cancer epithelial cells. Importantly, we observe that in human hyperplastic and cancerous prostate glands PIM1 is also markedly elevated in prostate fibroblasts, suggesting an important role for this kinase in epithelial/stromal crosstalk. The ability of PIM1 to regulate the biologic activity of ... Read more >>

Cell. Signal. (Cellular signalling)
[2015, 27(1):135-146]

Cited: 10 times

View full text PDF listing >>



The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.

Kumar Saurabh, Michael T Scherzer, Parag P Shah, Alice S Mims, William W Lockwood, Andrew S Kraft, Levi J Beverly,

PIM kinases are a family of serine/threonine kinases involved in cell survival and proliferation. There is significant structural similarity between the three PIM kinases (PIM1, PIM2 and PIM3) and only few amino acid differences. Although, several studies have specifically monitored the role of PIM1 in tumorigenesis, much less is known ... Read more >>

Oncotarget (Oncotarget)
[2014, 5(18):8503-8514]

Cited: 18 times

View full text PDF listing >>



Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumors.

Shilpak Chatterjee, Krishnamurthy Thyagarajan, Pravin Kesarwani, Jin H Song, Myroslawa Soloshchenko, Jianing Fu, Stefanie R Bailey, Chenthamarkshan Vasu, Andrew S Kraft, Chrystal M Paulos, Xue-Zhong Yu, Shikhar Mehrotra,

T cells of the T helper (Th)17 subset offer promise in adoptive T-cell therapy for cancer. However, current protocols for ex vivo programming of Th17 cells, which include TGFβ exposure, increase the expression of CD39 and CD73, two cell surface ATP ectonucleotidases that reduce T-cell effector functions and promote immunosuppression. ... Read more >>

Cancer Res (Cancer research)
[2014, 74(21):6048-6059]

Cited: 20 times

View full text PDF listing >>



Metabolic dysfunction consistent with premature aging results from deletion of Pim kinases.

Shabana Din, Mathias H Konstandin, Bevan Johnson, Jacqueline Emathinger, Mirko Völkers, Haruhiro Toko, Brett Collins, Lucy Ormachea, Kaitlen Samse, Dieter A Kubli, Andrea De La Torre, Andrew S Kraft, Asa B Gustafsson, Daniel P Kelly, Mark A Sussman,

The senescent cardiac phenotype is accompanied by changes in mitochondrial function and biogenesis causing impairment in energy provision. The relationship between myocardial senescence and Pim kinases deserves attention because Pim-1 kinase is cardioprotective, in part, by preservation of mitochondrial integrity. Study of the pathological effects resulting from genetic deletion of ... Read more >>

Circ Res (Circulation research)
[2014, 115(3):376-387]

Cited: 17 times

View full text PDF listing >>



The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.

Bo Cen, Ying Xiong, Jin H Song, Sandeep Mahajan, Rachel DuPont, Kristen McEachern, Daniel J DeAngelo, Jorge E Cortes, Mark D Minden, Allen Ebens, Alice Mims, Amanda C LaRue, Andrew S Kraft,

MET, the receptor for hepatocyte growth factor (HGF), plays an important role in signaling normal and tumor cell migration and invasion. Here, we describe a previously unrecognized mechanism that promotes MET expression in multiple tumor cell types. The levels of the Pim-1 protein kinase show a positive correlation with the ... Read more >>

Mol. Cell. Biol. (Molecular and cellular biology)
[2014, 34(13):2517-2532]

Cited: 29 times

View full text PDF listing >>



The 2014 Surgeon General's report: "The health consequences of smoking--50 years of progress": a paradigm shift in cancer care.

Graham W Warren, Anthony J Alberg, Andrew S Kraft, K Michael Cummings,

Cancer (Cancer)
[2014, 120(13):1914-1916]

Cited: 76 times

View full text PDF listing >>



A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.

Przemyslaw W Twardowski, Jan H Beumer, C S Chen, Andrew S Kraft, Gurkamal S Chatta, Masato Mitsuhashi, Wei Ye, Susan M Christner, Michael B Lilly,

There is a need for efficacious therapies for metastatic castration-resistant prostate cancer (mCRPC) after disease progression on docetaxel. The SRC tyrosine kinase and its related family members may be important drivers of prostate cancer and can be inhibited by dasatinib. mCRPC patients, after one previous chemotherapy, started dasatinib at 70 ... Read more >>

Anticancer Drugs (Anti-cancer drugs)
[2013, 24(7):743-753]

Cited: 29 times

View full text PDF listing >>



Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells.

Ningfei An, Ying-Wei Lin, Sandeep Mahajan, Joshua N Kellner, Yong Wang, Zihai Li, Andrew S Kraft, Yubin Kang,

The genes and pathways that govern the functions and expansion of hematopoietic stem cells (HSC) are not completely understood. In this study, we investigated the roles of serine/threonine Pim kinases in hematopoiesis in mice. We generated PIM1 transgenic mice (Pim1-Tx) overexpressing human PIM1 driven by vav hematopoietic promoter/regulatory elements. Compared ... Read more >>

Stem Cells (Stem cells (Dayton, Ohio))
[2013, 31(6):1202-1212]

Cited: 15 times

View full text PDF listing >>



Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma.

David T Marshall, Stephen Ramey, Ali-Reza Golshayan, Thomas E Keane, Andrew S Kraft, Uzair Chaudhary,

BACKGROUND: This was a phase I study to find the maximum tolerable dose (MTD) of weekly docetaxel combined with high-dose intensity-modulated radiotherapy (IMRT) and androgen deprivation therapy (ADT). PATIENTS AND METHODS: Men with localized high-risk prostate cancer (HRPC) were treated with weekly docetaxel at 10 to 30 mg/m(2) concurrent with ... Read more >>

Clin Genitourin Cancer (Clinical genitourinary cancer)
[2014, 12(2):80-86]

Cited: 3 times

View full text PDF listing >>



Targeted glycoprotein enrichment and identification in stromal cell secretomes using azido sugar metabolic labeling.

Stephen M Roper, Marina Zemskova, Benjamin A Neely, Arch Martin, Peng Gao, E Ellen Jones, Andrew S Kraft, Richard R Drake,

Effectively identifying the proteins present in the cellular secretome is complicated due to the presence of cellular protein leakage and serum protein supplements in culture media. A metabolic labeling and click chemistry capture method is described that facilitates the detection of lower abundance glycoproteins in the secretome, even in the ... Read more >>

Proteomics Clin Appl (Proteomics. Clinical applications)
[2013, 7(5-6):367-371]

Cited: 8 times

View full text PDF listing >>



Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1.

Bo Cen, Sandeep Mahajan, Wenxue Wang, Andrew S Kraft,

The PI3K/AKT pathway is hyperactivated in prostate cancer but its effective therapeutic targeting has proven difficult. In particular, the antitumor activity of AKT inhibitors is attenuated by upregulation of receptor tyrosine kinases (RTK) through an uncharacterized feedback mechanism. In this report, we show that RNA interference-mediated silencing or pharmacologic inhibition ... Read more >>

Cancer Res (Cancer research)
[2013, 73(11):3402-3411]

Cited: 36 times

View full text PDF listing >>



Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Gary K Schwartz, William D Tap, Li-Xuan Qin, Michael B Livingston, Samir D Undevia, Bartosz Chmielowski, Mark Agulnik, Scott M Schuetze, Damon R Reed, Scott H Okuno, Joseph A Ludwig, Vicki Keedy, Petra Rietschel, Andrew S Kraft, Douglas Adkins, Brian A Van Tine, Bruce Brockstein, Vincent Yim, Christiana Bitas, Abdul Abdullah, Cristina R Antonescu, Mercedes Condy, Mark A Dickson, Shyamprasad Deraje Vasudeva, Alan L Ho, L Austin Doyle, Helen X Chen, Robert G Maki,

Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR. The expression of IGF-1R seems to be crucial for this effect. We investigated the safety and efficacy of the combination of the IGF-1R antibody cixutumumab and the mTOR inhibitor temsirolimus in patients with ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2013, 14(4):371-382]

Cited: 85 times

View full text PDF listing >>



Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice.

Ningfei An, Andrew S Kraft, Yubin Kang,

Pim (proviral insertion in murine lymphoma) kinases are a small family of constitutively active, highly conservative serine/threonine oncogenic kinases and have 3 members: Pim1, Pim2, and Pim3. Pim kinases are also implicated in the regulation of B- and T- cell responses to cytokines and hematopoietic growth factors. The roles of ... Read more >>

J Hematol Oncol (Journal of hematology & oncology)
[2013, 6:12]

Cited: 13 times

View full text PDF listing >>



Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer.

Houjian Cai, Sanaz Memarzadeh, Tanya Stoyanova, Zanna Beharry, Andrew S Kraft, Owen N Witte,

Elevation of the chromatin repression factor enhancer of zeste homolog (EZH2) is associated with progression and poor prognosis in several human cancers including prostate cancer. However, the mechanisms driving EZH2 expression are not fully understood. In this study, we investigated the functional synergy in prostate cancers in mice resulting from ... Read more >>

Cancer Res (Cancer research)
[2012, 72(18):4672-4681]

Cited: 21 times

View full text PDF listing >>



Advertisement

Disclaimer
1.1302 s